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ABSTRACT: Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptor-
mediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL
accumulation and foam cell conversion within diseased arteries. In this work, we harness nanotechnology to design and fabricate
a new class of nanoparticles (NPs) based on hydrophobic mucic acid cores and amphiphilic shells with the ability to inhibit the
uncontrolled uptake of modified lipids in human macrophages. Our results indicate that tailored NP core and shell formulations
repress oxLDL internalization via dual complementary mechanisms. Specifically, the most atheroprotective molecules in the NP
cores competitively reduced NP-mediated uptake to scavenger receptor A (SRA) and also down-regulated the surface expression
of SRA and CD36. Thus, nanoparticles can be designed to switch activated, lipid-scavenging macrophages to antiatherogenic
phenotypes, which could be the basis for future antiatherosclerotic therapeutics.
KEYWORDS: atherosclerosis, amphiphilic macromolecules, scavenger receptor, nanoparticle, macrophages, atherogenesis,
oxidized lipoproteins
■ INTRODUCTION
Atherosclerosis, defined by persistent inflammation and the
buildup of lipid-rich plaques in arterial walls, leads to life
threatening cardiovascular conditions such as myocardial
infarction, chronic stable angina, and stroke.1 This inflamma-
tion is triggered by high levels of deposited oxidized low density
lipoproteins (oxLDL) within arterial walls and contributes to
the formation of foam cells, the major constituent of arterial
plaque growth. It is well-known that the unregulated cellular
uptake of oxLDL by intimal macrophages is primarily mediated
through scavenger receptors.2−6 This cycle is self-perpetuated
through unregulated scavenger receptor replenishment and
oxLDL uptake.4 Therefore, new bioactive molecules that can
effectively intervene in the uptake of oxLDL via scavenger
receptors in a sustained manner can offer a rational approach to
manage atherosclerosis and can present potential therapeutic
targets for drug discovery.7−9
Our laboratories have proposed amphiphilic macromolecules
(AMs) that competitively bind to cells via scavenger receptors
and demonstrate the ability to inhibit uptake of oxLDL in IC21
macrophages,10,11 THP-1 monocytes,12−15 and cell lines
engineered with scavenger receptors.16 The chemical makeup
of these AMs comprises a sugar backbone that has been
acylated with lauroyl chloride followed by conjugation to 5 kDa
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poly(ethylene glycol) (PEG). Recently, a study was conducted
in which the AM micellar assemblies carrying a cholesterol
efflux drug were administered to injured carotid arteries of
Sprague−Dawley rats fed a high fat diet.12 The localized AMs
were able to inhibit macrophage retention and decrease
cholesterol accumulation in the intima.
Although thermodynamically assembled micelles are promis-
ing for the delivery of water insoluble therapeutics,17−19 such
assemblies are vulnerable to disruption (i.e., micelle dissolu-
tion) when introduced into a physiological environment.20,21
Since micelles are in a constant dynamic equilibrium between
the assembled state and unimers (single macromolecules) this
can lead to poor drug retention allowing the encapsulated drug
and/or unimer to partition into neighboring plasma proteins or
lipophilic sinks.19,22−27 To overcome these challenges, our lab
developed AM-based organic nanoparticles, composed of
hydrophobic solutes, using a kinetic process known as flash
nanoprecipitation (FNP).28−33 NPs fabricated under this
method are resistant to the thermodynamic instabilities of
unimer partitioning that are typically associated with
thermodynamic micellar formulations. Notably, the NPs
composed of an AM shell/corona and a hydrophobically
modified mucic acid core (M12) have shown the ability to
inhibit oxLDL uptake in human monocyte-derived macro-
phages (HMDMs), even in the presence of 20% serum, where
analogous micellar assemblies were ineffective at that serum
concentration.34
Despite the promise of the AM-based nanoparticles, the
antiatherogenic mechanism of action of the NPs remains to be
elucidated. Thus, the focus of this work was to utilize bioactive,
serum-stable AM-derived NPs and identify the critical macro-
molecular determinants for regulation of scavenger-receptor-
mediated mechanisms of foam cell formation and athero-
genesis. While prevalent pharmacologic factors, such as statins,
aim to systematically inhibit the synthesis of cholesterol,
approaches capable of managing atherosclerosis through the
regulation of scavenger receptor expression may be a more
lesion-directed, disease-specific treatment strategy. Insights
from our studies indicate that the amphiphilic macro-
molecule-based nanoparticles have a potent effect not only
on competitively inhibiting oxLDL uptake but also switching
macrophages to a more inherently antiatherogenic phenotype.
■ EXPERIMENTAL SECTION
Materials. Synthesis of the AMs and of the mucic acid
modified with lauroyl chloride (M12) was followed as described
Figure 1. Schematic of the flash nanoprecipitation process used to fabricate kinetically assembled nanoparticles (NPs) and the resultant library of
amphiphilic shell and hydrophobic core macromolecules. (A) To form colloidal stable NPs, complete homogeneous mixing between the solvent
(THF) and aqueous streams must be achieved. This mixing time is represented by τmix, and the NP formation time is represented by τflash. (B)
Structures and corresponding acronyms of amphiphilic macromolecule (AM) shell and hydrophobic core components used in the formulation of
NPs. (C) Table of NP composition including the core and shell materials as well as characterization including hydrodynamic diameters (Dh),
standard error of the mean (SEM) of the Dh (n = 2), polydispersity index (PDI), and ζ potential as measured by dynamic light scattering.
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previously.8,29 Materials used for NP fabrication include
tetrahydrofuran (THF) (Sigma-Aldrich), copolymer poly-
(styrene15-block-ethylene glycol114) (PS15PEG; Mn = 6600 g/
mol, PDI = 1.10) (Polymer Source), homopolymer polystyrene
(PS14; Mn = 1500 g/mol) was prepared as described
previously,35 and the hydrophobic fluorophore 2,2,10,10-
tetraethyl-6,14-bis(triisopropylsilylethynyl)-1,3,9,11-tetraoxa-di-
cyclopenta pentacene (EtTP-5) was gifted by Prof. John
Anthony from the University of Kentucky, Department of
Chemistry (Lexington, KY). Cell culture, blocking assay, flow
cytometry, and immunocytochemistry materials include human
buffy coats (The Blood Center of NJ), macrophage colony
stimulating factor (M-CSF) (PeproTech), RPMI-1640
(ATCC), penicillin/streptomycin (Lonza), Ficoll-Paque pre-
mium 1.077g/mL (GE Healthcare), FBS and Hoechst 33342
(Life Technologies), 3,3′-dioctadecyloxacarbocyanine (DiO)
labeled oxLDL (Kalen Biomedical), and unlabeled oxidized
LDL (Biomedical Technologies Inc.).
Nanoparticle Fabrication and Characterization. Nano-
particles were fabricated via a flash nanoprecipitation process
(Figure 1A) described previously.29 Briefly, the shell material,
either 100% AM or a combination of M12PEG and PS15PEG,
were dissolved in THF at 40 mg/mL and the core material, M12
and/or PS14, were dissolved at 20 mg/mL, to result in a shell to
core weight ratio of 2:1. Five hundred microliters of the THF
stream was mixed with 700 μL of the aqueous stream via a
confined impinging jet mixer, after which the stream was
immediately dispersed into 3.8 mL of picopure water. The NPs
were dialyzed 2× against picopure water for removal of the
THF. Fluorescent NPs were fabricated by coprecipitating 2.5
wt % core ETtP5 (2 ,2 ,10 ,10- tetraethy l -6 ,14-b is -
(triisopropylsilylethynyl)-1,3,9,11-tetraoxa-dicyclopenta[b,m]-
pentacene)36 with 97.5 wt % core (M12 and/or PS14).
Following dialysis, the NPs were characterized by dynamic
light scattering (DLS) using a Malvern-Zetasizer Nano Series
DLS detector with a 22 mW He−Ne laser operating at λ =
632.8 nm using general purpose resolution mode. Hydro-
dynamic diameters (peak size from intensity distribution), and
polydispersity indices (PDI) were obtained by diluting the NPs
10-fold in picopure water (Figure 1C). The structures of the
different amphiphilic shells and hydrophobic cores used for NP
fabrication can be found in Figure 1B.
Peripheral Blood Mononuclear Cell Isolation and
Culture. Peripheral blood mononuclear cells (PBMCs) were
isolated from human buffy coats by Ficoll-Paque (1.077 g/mL)
density gradient and ACK lysis of red blood cells as described
previously.29 Cells were washed in PBS, centrifuged at 300g to
remove platelets, and added to BD Falcon T175 flasks at a
concentration of 2.85 million cells/mL in base media (RPMI
1640 supplemented with 10% FBS and 1% penicillin/
Figure 2. Roles of core versus shell components of the NPs on antiatherogenic activity were elucidated. (A) Schematic showing the experimental
design of cultured HMDMs treated with oxLDL and different NP formulations and then assessed for the ability of the NPs to inhibit uptake of the
modified LDL. (B,C) The NP shell and core contribute differentially to oxLDL uptake inhibition, wherein the “bioactive” core had a more
pronounced effect. The data were acquired by flow cytometry analysis of HMDMs. (B) NPs with varying core chemistry are composed of a fixed
100% nonbioactive PS15PEG114 shell formulated with differing core combinations of bioactive M12 and nonbioactive PS14. (C) NPs changing in the
shell chemistry and composed of a fixed 100% bioactive M12 core formulated with differing shell combinations of M12PEG and nonbioactive
PS15PEG114. Data are from n = 3 experiments (error bars = ±SEM). OxLDL uptake by HMDMs was evaluated after 24 h co-incubation of oxLDL (5
μg/mL) and NPs (1.5 × 10−5 M) in 10% FBS. (B,C) Statistical analysis was conducted over the entire data presented in these parts of this figure so
comparisons can be made between all NP groups. Treatments with the same letter are not statistically significant from one another, and the asterisk
(*) indicates statistical significance from the oxLDL control. Statistical significance corresponds to p ≤ 0.05.
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streptomycin). After 24 h of incubation at 37 °C and 5% CO2,
adherent cells were selected and incubated for an additional 7
days in the base media containing 50 ng/mL M-CSF for
differentiation into HMDMs. Next, cells were plated into the
desired well plate (flow cytometry) or Labtek chamber
(microscopy imaging) at a concentration of 150,000 cells/mL
and allowed to rest for 24 h before the addition of treatments.
OxLDL Uptake. To evaluate the influence of NPs on
oxLDL uptake, HMDMs were incubated with fluorescent DiO
oxLDL (1 μg/mL, Kalen Biomedical) and unlabeled oxLDL (4
μg/mL, Biomedical Technologies) with or without NPs (1.5 ×
10−5 M) of each chemistry in base media for 24 h (Figure 2A).
Oxidized LDL with a relative electrophoretic mobility between
1.8 and 2.1 was chosen for these studies as it correlates to a
mild to high level of oxidation and is representative of the
highly oxidative states of LDL encountered by macrophages in
developing plaques.37 Next, the cells were prepared for analysis
on the flow cytometer as described in the scavenger receptor
blocking assay. DiO oxLDL fluorescence was quantified via flow
cytometry with a FACSCalibur (Becton Dickinson) by
collecting 10,000 events per sample and analyzed with Flow
Jo software (Treestar) by quantifying the DiO oxLDL MFI. A
minimum of three experimental replicates was conducted for
this study. Data is presented as % inhibition of oxLDL uptake
and determined by the following equation:
= −
×
%inhibition of oxLDL uptake 100 100
DiO oxLDL MFI of treatment sample
DiO oxLDL MFI of oxLDL only control sample
Scavenger Receptor-Mediated NP Uptake. To evaluate
the influence of blocking agents on NP uptake, HMDMs were
incubated with polyinosinic acid (10 μg/mL, Sigma-Aldrich) or
CD36 monoclonal antibody (2 μg/mL, clone JC63.1, Cayman
Chemical) in base media for 1 h at 37 °C. The corresponding
isotype control to human CD36 monoclonal antibody, purified
mouse IgA, κ (BD Pharmingen, clone M18-254) was included
in this experimental protocol to test for nonspecific antibody
binding. Following the incubation, blocking agents were
removed, cells washed, and then incubated with fluorescent
NPs (1.5 × 10−5 M, 2.5 wt % core ETtP5 with 97.5 wt % core
M12) of distinct compositions for 6 h (Figure 3A). Next, the
cells were prepared for flow cytometry by washing and then
incubation with 2 mM EDTA for 15 min on cold packs. After
vigorously pipetting each sample the cells were transferred to 5
mL polystyrene tubes, centrifuged at 1000 rpm for 10 min, and
then fixed with 1% paraformaldehyde (PFA). NP fluorescence
was quantified via flow cytometry with a FACSCalibur (Becton
Dickinson) by collecting 10,000 events per sample and
analyzed with Flow Jo software (Treestar) by quantifying the
Figure 3. Scavenger receptor A (SRA) mediated NP uptake was dictated primarily by the M12 NP core. All M12 core containing NPs resulted in the
highest level of NP uptake, which was confirmed to be via SRA. Minimal NP uptake was observed with the NP formulation with the PS14 core. (B−
E) NP association with HMDMs and (F) the basal control were obtained by flow cytometry. (A) NP uptake, determined in panels B−E, was
evaluated in HMDMs after a 1 h preblocking step with polyinosinic acid and a subsequent incubation with fluorescent NPs (1.5 × 10−5 M) for 6 h in
the presence of 10% FBS. Percent NP uptake via SRA was determined by comparing the HMDM mean fluorescence intensity (MFI) of the NP MFI
with and without SRA blocking. (B,D) NPs changing in the core chemistry are composed of a fixed 100% nonbioactive PS15PEG114 shell formulated
with differing core combinations of bioactive M12 and nonbioactive PS14. (C,E) NPs changing in the shell chemistry and composed of a fixed 100%
bioactive M12 core formulated with differing shell combinations of M12PEG and nonbioactive PS15PEG114. (D−F) Representative histograms of
HMDM NP MFI (x-axis) vs count (y-axis) with (black) and without (light gray) SRA blocking and basal control (blue). (B,C) Statistical analysis
was conducted over the entire data presented in these parts of this figure so comparisons can be made between all NP groups. Data is from a
minimum n = 3 (error bars = ±SEM). Treatments with the same letter are not statistically significant from one another and statistical significance
corresponds to p ≤ 0.05.
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NP mean fluorescence intensity (MFI) of the HMDM
population. A minimum of three experimental replicates was
conducted for this study. The degree of inhibition of NP uptake
caused by each blocking agent was determined by the following
equation:
=
×
%NP uptake 100
NP MFI sample pretreated with blocking agent
NP MFI sample not pretreated with blocking agent
Scavenger Receptor Surface Expression. To evaluate
the influence of NPs on cell surface scavenger receptor
expression, HMDMs were incubated with unlabeled oxLDL
(5 μg/mL) with or without NPs of each chemistry for 24 h.
Following the incubation, treatments were removed, and cells
were prepared for evaluation via flow cytometry or microscopy.
For flow cytometry preparation, the cells were washed in
blocking buffer (0.5% bovine serum albumin (BSA), 0.1%
sodium azide, and 1% normal goat serum in PBS), and
incubated with 2 mM EDTA diluted in blocking buffer for 15
min on cold packs. After vigorously pipetting each sample they
were transferred to 5 mL polystyrene tubes and centrifuged at
1000 rpm for 10 min. Next, supernatants were decanted, and
the cells were incubated for 1 h at 4 °C with monoclonal
antihuman SR-AI/MSR1-phycoerythrin (PE) antibody (clone
351615, R&D Systems) and APC antihuman CD36 antibody
(clone: 5-271, Biolegend) or their corresponding isotype
control APC mouse IgG2a, κ (clone: MOPC-173, Biolegend),
and mouse IgG2B PE (clone 133303, R&D systems).
Following antibody incubation, the cells were washed twice
and then fixed with 1% PFA. CD36 APC and SRA-1 PE
fluorescence was quantified via flow cytometry with a Gallios
(Beckman Coulter) by collecting 10,000 events per sample and
analyzed with Flow Jo software (Treestar) by quantifying the
MFI of CD36 and SRA-1. A minimum of 3 experimental
replicates were conducted for this study. All data were
normalized to the basal condition. For microscopy, cells were
washed with PBS and then blocked with 0.5% bovine serum
albumin (BSA), 0.1% sodium azide, and 10% normal goat
serum in PBS for 2 h. Next, cells were incubated for 3 h at 25
°C with monoclonal antihuman SR-AI/MSR1-phycoerythrin
(PE) antibody (clone 351615, R&D Systems) and APC
antihuman CD36 antibody (clone: 5-271, Biolegend) or their
corresponding isotype control APC mouse IgG2α, κ (clone:
MOPC-173, Biolegend), and PE mouse IgG2β (clone 133303,
R&D systems). Following the incubation they were washed and
then incubated with the secondary antibody, goat antimouse
IgG2α alexa fluor 488 (SR-A1 conditions) or anti- mouse
IgG2β alexa fluor 647 (CD36 conditions) for 1 h. They were
then washed, fixed in 4% PFA, and counterstained with
Hoechst 33342 before imaging on a Leica TCS SP2 confocal
microscope. Representative images of CD36 and SRA receptor
expression in HMDMs were obtained with ImageJ. The change
in scavenger receptor expression was determined by the
following equation:
= ×
%SR expression relative to oxLDL treatment
100
SR MFI of treatment sample
SR MFI of oxLDL only control sample
Scavenger Receptor Gene Expression. To evaluate the
influence of NPs on scavenger receptor gene expression,
HMDMs were incubated with unlabeled oxLDL (5 μg/mL)
with or without NPs of each chemistry in base media for 24 h.
Following the incubation, treatment supernatants were
removed and RNA was isolated with RNeasy Plus Mini Kit
(Qiagen) according to the manufacturer’s protocol. Reverse
transcription was carried out using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) following the
manufacturer’s protocol and performed in an Idaho Technol-
ogy thermal cycler. Human SRA, CD36, and β-actin primers
were designed by Harvard Primer Bank and synthesized by
Integrated DNA Technology. Quantitative real-time polymer-
ase chain reaction (qRT-PCR) was performed using Fast SYBR
Green Master Mix (Applied Biosystems) per manufacturer’s
protocol in a LightCycler 480 (Roche Applied Science).
Crossing points were determined using the second derivative
maximum method in LightCycler 480 SW 1.5 software. Data is
presented as a fold change calculated by ΔΔCt, using β-actin as
the endogenous control gene and normalized to basal.
Statistical Analysis. Statistical analyses were performed
using JMP by SAS. Statistical significance (p ≤ 0.05) was
determined using a one-way ANOVA with Tukey’s posthoc test
for comparisons between multiple groups.
■ RESULTS
Effect of NP Shell and Core on the Inhibition of oxLDL
Uptake in Macrophages. NPs composed of bioactive shell
(M12PEG) and core (M12) components (Figure 1B), known to
possess potent oxLDL inhibition activity, were fabricated and
evaluated at an optimized concentration of 1 × 10−5 M
(Supporting Information Figure 3A). As graded controls of
bioactivity, additional NPs were designed and fabricated using
differential amounts of nonbioactive shell (PS15PEG) and core
(PS14) components (Figure 1B). To discern the role of the core
on NP bioactivity, NPs composed of a nonbioactive shell with
different combinations of bioactive and nonbioactive cores were
fabricated (top three rows of Figure 1C), and to discern the
role of the shell on NP bioactivity and to identify synergies
between the core and shell, NPs composed of a bioactive core
with different combinations of bioactive and nonbioactive shells
were fabricated (bottom three rows of Figure 1C). This enables
one to deconstruct structure−activity relationships pertaining
to the role of the shell versus core at inhibiting oxLDL uptake
(Figure 2B). In this study, HMDMs were simultaneously
exposed to both oxLDL and NPs, and the uptake of oxLDL was
evaluated 24 h later via flow cytometry. The results in Figure 2B
are from NPs composed of nonbioactive (100% PS15PEG) shell
formulated with different core combinations of bioactive M12
and nonbioactive PS14, while Figure 2C represents NPs
composed of a bioactive (100% M12) core formulated with
different shell combinations of M12PEG and nonbioactive
PS15PEG (all NP formulations evaluated are listed in Figure
1C). One can better understand the importance of the bioactive
core, M12, by comparing the change in oxLDL inhibition
capacity of the nonbioactive shell NPs (100% PS15PEG) as the
content of M12 is increased and the content of PS14 is decreased
within the core (Figure 2B), which resulted in a 2.8-fold
increase in oxLDL uptake-inhibition capacity. However, one
can evaluate the importance of the bioactive, M12PEG, in the
shell by comparing the change in oxLDL uptake-inhibition
potential in Figure 2C of the bioactive core NPs (100% M12) as
the shell PS15PEG content is decreased and the M12PEG
content is increased (shifting from the 100% PS15PEG shell to
100% M12PEG shell formulations containing 100% M12), which
resulted in a significant but smaller increase in inhibition
Molecular Pharmaceutics Article
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potential of 1.4-fold. Overall, all M12-core containing NP
formulations resulted in a significant increase in inhibition
potential from the oxLDL control. This was even observed with
the nonbioactive 100% PS15PEG shell formulation, inhibiting
53% of oxLDL uptake. However, in this same shell formulation,
when the bioactive, M12, core is replaced with 100% of the
nonbioactive, PS14 core, the oxLDL uptake-inhibition capacity
drops markedly to 19%. This level of inhibition is not
statistically significant from the oxLDL control. All NP
formulations tested revealed to have no toxic effect on the
HMDMs (Supporting Information Figure 1).
Contribution of the NP Shell and Core to Scavenger
Receptor Binding. The ability of the NPs to inhibit oxLDL
uptake in HMDMs as seen in Figure 2 may be due to
competitive binding between the NPs and oxLDL to scavenger
receptors. It is well documented that the unregulated uptake of
oxLDL is primarily mediated through scavenger receptors such
as SRA and CD36.1−4 Thus, the ability of NPs to bind and be
internalized by these receptors on HMDMs was evaluated. The
results, presented in Figure 3B,C, demonstrate that M12-core
containing NP formulations are internalized via SRA albeit with
less internalization via CD36 (Supporting Information Table
1). However, it is interesting to note that NP internalization
trends via SRA are similar to those via CD36. Between 44 and
59% internalization via SRA was observed for all formulations
containing M12, but there was no statistical difference in
internalization between any of these formulations. Changes in
the shell composition did not appear to affect internalization via
SRA as long as the M12 core was present (Figure 3C).
However, the formulation without a bioactive core or shell,
100% PS14 core and 100% PS15PEG shell, resulted in very low
overall cellular internalization (Supporting Information Figure
2) and especially via SRA (Figure 3B), which is why the
histograms in Figure 3D, for this formulation, appear at a lower
fluorescence intensity. Significant NP internalization was only
observed in the M12 containing NP formulations (Supporting
Information Figure 2). The ability of each NP formulation to
be internalized via SRA is further represented in the histograms
of Figure 3D,E in which the change in cellular fluorescence
attributed to NP uptake via SRA can be identified by comparing
the shift from the outlined histogram (NP uptake without SRA
blocked) to the solid black histogram (NP uptake with SRA
blocked). A further shift of the solid histogram to the left
(lower MFI values) indicates a more pronounced effect of SRA
blocking on NP uptake.
Effect of NP Shell and Core on Scavenger Receptor
Surface and Gene Expression. The presence of scavenger
receptors on the surface of plaque-resident macrophages is
essential for the unregulated uptake of oxLDL molecules.1−4 To
examine the ability of the different NP formulations to mediate
scavenger receptor expression on the surface of the HMDMs in
the presence of modified lipids, the expression of SRA-1 (SRA
isoform 1) and CD36 was evaluated after cotreatment with
different NP formulations and oxLDL (Figure 4). All NP
formulations containing 100% M12 in the core engendered a
pronounced decrease in the level of surface expression of SRA
(40−49%) and CD36 (52−69%) as compared to the oxLDL
control, Figure 4A,B. A trend can be observed in Figure 4A
correlating the level of SRA and CD36 expression with the
amount of M12 in the NP core, with the expression of both
scavenger receptors decreasing as the proportion of the M12-
core composition was increased. As seen with SRA binding, the
shell formulation did not have a significant effect on scavenger
receptor expression if 100% M12 core was present (Figure 4B).
As to be expected, the formulation containing the 100% PS14
core and 100% PS15PEG shell had a minimal effect on CD36
Figure 4. HMDMs exhibit NP influenced down-regulation of scavenger receptors, which is primarily regulated by the core, M12. (A,B) Protein-level
surface expression of SRA and CD36 receptors was probed using flow cytometry analysis of HMDMs after 24 h incubation of NPs (1.5 × 10−5 M) +
oxLDL (5 μg/mL) in the presence of 10% FBS. (A) NPs changing in the core chemistry are composed of a fixed -100% nonbioactive PS15PEG114
shell formulated with differing core combinations of bioactive M12 and nonbioactive PS14. (B) NPs changing in the shell chemistry and composed of
a fixed 100% bioactive M12 core formulated with differing shell combinations of M12PEG and nonbioactive PS15PEG114. Scavenger receptor
expression (y-axis) is shown as a percent of the oxLDL control. C) Scavenger receptor gene expression was evaluated using q-RT-PCR analysis of
HMDMs after 24 h incubation of NPs (1.5 × 10−5 M) + oxLDL (5 μg/mL) in the presence of 10% FBS. Data are from a minimum n = 3 (error bars
= ±SEM). Statistical analysis was conducted over both parts A and B of this figure so comparisons can be made between all NP groups. Treatments
with the same letter are not statistically significant from one another, and the asterisk (*) indicates statistical significance from the oxLDL control.
Statistical significance corresponds to p ≤ 0.05 for SRA and CD36 expression.
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and SRA expression and was insignificant from the oxLDL
control (Figure 4A). Consistent with surface expression, the
100% M12PEG shell 100% M12 core NP formulation caused a
down-regulation of mRNA gene expression of both receptors
(Figure 4C).
A more in-depth assessment of the scavenger receptor
phenotype of the HMDMs following NP treatment can be seen
in Figure 5A,B and can be compared to the oxLDL control in
Figure 5C. The dark blue area of the pie charts represent highly
atherogenic HMDMs that are positive for both SRA and CD36,
whereas the lighter two shades of blue represent less
atherogenic phenotypes, mid shade representing the population
negative for both SRA and CD36, and the lightest shade of blue
representing populations positive for only one scavenger
receptor. Interestingly, the best NP inhibitor of oxLDL uptake,
100% M12PEG shell 100% M12 core, caused a pronounced shift
in scavenger receptor phenotypes by increasing the population
of cells negative for both receptors (twice as many as the
Figure 5. The most bioactive NPs shift the macrophage atherogenic phenotype from a population double positive for scavenger receptors
(SRA+CD36+) to a population positive for only either scavenger receptor (SRA+CD36− and SRA−CD36+) or neither scavenger receptor
(SRA−CD36−). Treatment groups include (A) NPs with varying core chemistry composed of a fixed 100% nonbioactive PS15PEG114 shell
formulated with differing core combinations of bioactive M12 and nonbioactive PS14, (B) NPs with varying shell chemistry composed of a fixed 100%
bioactive M12 core formulated with differing shell combinations of M12PEG and nonbioactive PS15PEG114, and (C) oxLDL control. The HMDM
scavenger receptor phenotypes presented in the top charts were obtained by flow cytometry, and below each chart are representative
immunofluorescence micrographs for SRA and CD36 for each treatment group (SRA in red, CD36 in green, and cell nuclei in blue). Scavenger
receptor surface expression was evaluated in HMDMs after 24 h incubation of NPs (1.5 × 10−5 M) + oxLDL (5 μg/mL) in the presence of 10%
FBS. Flow cytometry data are from a minimum n = 3. (D) The proposed mechanism of action by which NPs inhibit oxLDL uptake in HMDMs.
Atherosclerosis, influenced by the unregulated uptake of oxLDL, can potentially be inhibited with NP formulations that competitively bind scavenger
receptors, become internalized, and cause a decrease in scavenger receptor surface expression, thus leading to a more sustained antiatherogenic
phenotype in macrophages.
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oxLDL control) and decreasing the population of cells positive
for both receptors (about half as many as the oxLDL control).
Cells treated with NP formulations composed of 100% M12
core demonstrated similar athero-protective scavenger receptor
phenotypes (Figure 4B), whereas treatment with the non-
bioactive 100% PS14 core and 100% PS15PEG shell did not alter
the HMDM phenotype from that observed with the oxLDL
control (Figures 4A,C). Images representative of the changes in
scavenger receptor expression for each treatment can be seen
below each pie chart. While expression of SRA is much less
intense than CD36, the images demonstrate that a larger
population of the oxLDL and nonbioactive (100% PS14 core
and 100% PS15PEG shell) NP treated HMDMs are positive for
both scavenger receptors versus the HMDMs treated with the
M12-core containing formulations.
■ DISCUSSION
Management of the uncontrolled uptake of oxLDL by cells of
actively developing atherosclerotic plaques, primarily macro-
phages, is a key target for therapeutic drug design and
development.2 Specifically, regulation of the scavenger receptor
expression could be an effective strategy to prevent further
accumulation of oxLDL and foam cell formation at the site of
the atherosclerotic lesions. CD36 and SRA have been
demonstrated to play a critical role in atherosclerotic lesion
development, modified lipid accumulation, and foam cell
formation in a cardiovascular disease mouse model.38 Herein,
we have fabricated a broad sublibrary of NPs to identify the
critical macromolecular determinants for regulation of scav-
enger receptor-mediated mechanisms of foam cell formation
and atherogenesis.
The fabrication of a range of NP formulations composed of
bioactive and nonbioactive core and shell materials allowed us
to discern the roles that the NP core and shell have on these
major serial phenomena: SRA mediated-uptake and the
regulation of scavenger receptor gene and surface expression,
which together are able to repress the uptake of oxLDL. The
proposed mechanism of action is depicted in Figure 5D. The
core of the NP, composed of the bioactive M12, proved to be
the most essential component for internalization via SRA and
modulating the surface expression of scavenger receptors, SRA
and CD36, causing a shift to a less atherogenic cellular
phenotype (cells positive for neither or only one of the
scavenger receptors vs cells positive for both). However, both
the core and shell of the NP demonstrated importance in
inhibiting oxLDL uptake, which suggests that they may have
distinct yet significant mechanisms of bioactivity.
Upon evaluation of the bioactive shell, M12PEG, it is clear
that it contributes further to the increase in oxLDL inhibition
potential of the NP. However, changes in the shell bioactive
component, M12PEG, do not appear to have an effect on the
NP uptake via SRA or on the regulation of scavenger receptor
expression. This suggests that the M12PEG shell, in the NP
formulation with a M12 core, is able to inhibit the uptake of
oxLDL via alternate mechanisms. The M12PEG shell of the NP
could allow for additional interactions with the cell (i.e.,
nonspecific binding to the lipid bilayer39), which would enable
the NPs to occupy more of the cell surface and carry out
additional oxLDL inhibition. Recent studies in our laboratories
using lipid bilayers support this hypothesis of considerable
membrane insertion by M12PEG.
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While the amphiphilic shell is integral for stabilization of the
hydrophobic core and for enabling cellular interactions, one of
the striking new findings of this study is that the core material
of the NP plays a more influential role on scavenger receptor-
mediated uptake than the shell. The majority of the NP shell is
composed of PEG, a material known to be nonfouling, thus
limiting interaction with proteins.40 The designated length of
the PEG coating allows stable transport through physiological
fluids but is short enough to allow for exposure of the
hydrophobic and electrostatic charge associated with the core-
PEG interface as it approaches the cellular membrane with
cationic SRA residues. This would allow for electrostatic
interactions between the negatively charged NP core and the
positively charged surface scavenger receptors and/or the
cellular membrane. Alternatively, as the NP approaches the
cellular membrane, a portion of the M12PEG shell may partition
from the NP to the cellular membrane exposing portions of the
hydrophobic core. However, this interaction between cellular
scavenger receptors and the NP core does not destabilize the
NP based on recent work by York et al., who showed that the
NPs remain intact with the shell and core components
localized, soon after cellular binding and internalization.34
This type of interaction (i.e., between the hydrophobic NP core
and cell surface molecules) has been reported in the literature
with some cell types having preferential attachment to
hydrophobic polymers.41 While we have demonstrated in this
work that the NPs clearly interact with the HMDMs through
SRA-mediated internalization, it is conceivable that there may
be an extracellular interaction between the NPs, particularly
serum-disrupted NPs, and the oxLDL. However, coincubation
studies with NPs and oxLDL suggest that there was no
detectable aggregation or increase in NP size (Supporting
Information, Figure 3E). This is to be expected as the NPs are
slightly negatively charged (as indicated by the zeta potential in
Figure 1C) and have a PEG shell so any unimer interaction
with highly oxidized oxLDL is unlikely since oxLDL itself is
negatively charged.
Following scavenger receptor interactions, we hypothesize
that the NPs are actively internalized, leading to continued
downstream bioactive signaling including scavenger receptor
down-regulation. While all M12 core NPs were readily
internalized via SRA, the NPs with more M12 in the core
demonstrated a stronger ability to lower cellular expression of
CD36 and SRA, which was sustained for up to 48 h with the
most bioactive formulation (Supporting Information Figure
3D). Not only did the M12-core formulations decrease the
amount of scavenger receptors on the cell surface but the 100%
M12PEG shell with 100% M12 core formulation caused a
doubling in the population of cells completely deficient of both
key surface scavenger receptors. A shift of this magnitude in the
scavenger receptor expression has not been reported before in
human macrophages. It was confirmed that the surface receptor
down-regulation is not just a factor of NP uptake and receptor
depletion but is accompanied by, and is likely caused by, a
decrease in the transcription of mRNA responsible for
translation of these proteins. To further investigate the
potential of NP interactions with oxLDL and this influence
on NP bioactivity, scavenger receptor regulation was evaluated
in the presence of only NPs. It was observed that scavenger
receptor surface and gene expression were down-regulated in
HMDMs; demonstrating that this effect is independent of
oxLDL-NP interactions (Supporting Information Figure 3B,C).
Furthermore, this 24 or 16 h NP preincubation in HMDMs
served as a sufficient treatment to maintain inhibition of
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subsequent oxLDL internalization (Supporting Information
Figure 3B).
The NP uptake and down-regulation of cellular scavenger
receptor expression correlates strongly with the inhibition of
oxLDL uptake. Even with the NP formulation composed of the
nonbioactive shell, PS15PEG, the presence of the M12 core was
able to increase oxLDL inhibition by 2.8-fold as compared to
the nonbioactive PS14 core. Such effects on scavenger receptor
expression have been reported in vitro with smooth muscle cells
and macrophages42,43 and in vivo with hypercholesterolemic
rabbits44 following treatment with α-tocopherol. The M12 core
NPs evaluated in this work appear to be functioning in a similar
manner as α-tocopherol; however, the signaling pathway that α-
tocopherol influences to down-regulate CD36 is largely
unknown.42 This consistent bioactivity may be due to the
similarities in the chemical structures of α-tocopherol and the
lauroyl side chains of the M12, which may facilitate hydrophobic
interactions. The ability of M12 core NPs to alter scavenger
receptor expression is possibly a concurrent effect of NP
binding and blocking of scavenger receptors (providing a
protective coating at the cell surface) and downstream
intracellular effects including NP internalization and exposure
to acidic vesicles in the macrophage. By binding scavenger
receptors, the NPs would minimize interactions with oxLDL
and disable downstream pathways, which lead to receptor
replenishment. NPs that are internalized would likely encounter
an enzyme rich environment, which may facilitate the release of
M12 from the NPs, enabling further disruption of receptor
replenishment pathways. It is possible that the M12 may be
interfering with the reduction or phosphorylation of tran-
scription factors responsible for upregulation of gene expression
or with the PPARγ-dependent nuclear receptor signaling
pathway responsible for scavenger receptor replenishment;37
however, these mechanisms remain to be elucidated. Since
oxLDL binding via CD36 has been shown to be a self-
perpetuating cycle of unregulated uptake and receptor
replenishment,4 the proposed NP formulations could have
two key concerted effects: the disruption of this cycle and a
decrease in scavenger receptor access. Furthermore, cholesterol
efflux has been linked to the decrease in CD36 expression,4
again exemplifying the importance of scavenger receptor down-
regulation for the management of atherosclerosis.
■ CONCLUSIONS
We have advanced a new class of nanotherapeutics that can
target macrophage scavenger receptors and repress the receptor
atherogenic activity. We have identified the bioactive
components of nanoparticles responsible for controlling
expression of scavenger receptors, SRA and CD36, involved
in the self-perpetuating cycle of unregulated oxLDL uptake and
receptor replenishment. The hydrophobic core component of
the NPs attenuated both the extracellular interactions of oxLDL
with scavenger receptors and the intracellular events that
further repress the uptake of oxLDL. A major finding of this
study is the ability of bioactive nanoparticles to switch highly
atherogenic macrophages to an athero-resistant phenotype,
which could be the basis for the emergent design of
nanomedicines targeted toward atherosclerotic plaques.
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